GlassScriptPhysician profile
William J Jawien
NPI 1417904020
$11,777.91
in general payments reported to CMS, 2019-2025
66 companies · $1,673 in 2025
The $1,673 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $1,021 · 2021: $1,799 · 2022: $1,925 · 2023: $1,672 · 2024: $2,328 · 2025: $1,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,593 · Education: $79.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,592.82 |
| Education | $79.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,246.50 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,146.20 | 2019-2025 | Lynparza, Calquence, Tagrisso |
| Celgene Corporation | $981.83 | 2021-2025 | Opdualag, Pomalyst, Reblozyl |
| Daiichi Sankyo INC. | $674.72 | 2020-2025 | Enhertu, Injectafer, Vanflyta |
| Glaxosmithkline, LLC. | $546.06 | 2019-2025 | Zejula, Jemperli, Ojjaara |
| Exelixis INC. | $515.34 | 2019-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $506.98 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $408.60 | 2019-2025 | Onivyde, Tazverik |
| Amgen INC. | $385.10 | 2019-2022 | |
| Abbvie INC. | $309.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $302.29 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $269.01 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Sobi, INC | $249.67 | 2022-2025 | |
| Kite Pharma, INC. | $236.13 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $235.23 | 2019-2023 | Epkinly, Imbruvica |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $226.37 | 2019-2023 | Imbruvica, Darzalex |
| Genentech USA, INC. | $218.08 | 2019-2024 | Phesgo, Polivy, Tecentriq |
| Genzyme Corporation | $215.08 | 2019-2025 | |
| Incyte Corporation | $212.52 | 2019-2025 | Monjuvi, Jakafi, Niktimvo |
| Gilead Sciences, INC. | $198.12 | 2019-2024 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $190.82 | 2019-2024 | Libtayo |
| Octapharma USA, INC. | $186.53 | 2019 | |
| Seagen INC. | $154.81 | 2019-2023 | Padcev |
| Springworks Therapeutics, INC. | $147.33 | 2024-2025 | Ogsiveo |
| Pharmaessentia USA Corporation | $146.17 | 2023-2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $136.13 | 2019-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Karyopharm Therapeutics INC. | $118.21 | 2020-2025 | Xpovio |
| Pfizer INC. | $115.33 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $99.54 | 2019-2023 | Ultomiris |
| Array Biopharma INC | $95.31 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Spectrum Pharmaceuticals INC. | $94.83 | 2019 | |
| Beigene USA, INC. | $86.70 | 2021-2024 | Brukinsa |
| Tersera Therapeutics LLC | $83.90 | 2019 | |
| Servier Pharmaceuticals LLC | $81.01 | 2022-2025 | |
| Emd Serono, INC. | $80.03 | 2019-2024 | |
| Dova Pharmaceuticals | $72.44 | 2020-2021 | |
| Stemline Therapeutics INC. | $63.04 | 2024 | Orserdu, Elzonris |
| Coherus Oncology, INC. | $62.09 | 2020-2021 | |
| Eisai INC. | $56.92 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.49 | 2019 | |
| G1 Therapeutics, INC. | $44.13 | 2022 | |
| Genmab U.S., INC. | $43.52 | 2025 | Epkinly |
| Agios Pharmaceuticals, INC. | $41.76 | 2021-2025 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $37.15 | 2021-2025 | Romvimza, Qinlock |
| Sirtex Medical INC | $35.35 | 2024 | Sir-Spheres Microspheres |
| Astellas Pharma US INC | $34.65 | 2019-2024 | Padcev |
| Tempus Ai, INC | $28.17 | 2025 | Xt Cdx |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Immunogen, INC. | $23.58 | 2023 | Elahere |
| Cumberland Pharmaceuticals, INC. | $20.96 | 2025 | Sancuso |
| Morphosys, US INC. | $20.26 | 2021 | |
| Novocure INC. | $17.51 | 2025 | Optune Lua (Novottf-200t) |
| Blueprint Medicines Corporation | $17.10 | 2021 | |
| Pharmacosmos Therapeutics INC. | $16.47 | 2025 | Monoferric |
| Jazz Pharmaceuticals INC. | $16.38 | 2020 | |
| Acrotech Biopharma INC. | $15.88 | 2021 | |
| Heron Therapeutics, INC. | $15.15 | 2022 | |
| Puma Biotechnology, INC. | $15.02 | 2021 | |
| Taiho Oncology, INC. | $14.87 | 2021 | |
| Beone Medicines USA, INC. | $14.34 | 2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.79 | 2024 | Gilotrif |
| Kyowa Kirin, INC. | $13.67 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.02 | 2019 | |
| Epizyme, INC. | $12.92 | 2022 | |
| Tesaro, INC. | $11.97 | 2019 | |
| Advanced Accelerator Applications | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Jawien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.